Profusa shares surge 19.94% premarket as late-breaking clinical trial update accepted for Paris Vascular Insights 2025 presentation.

Profusa (Nasdaq: PFSA) surged 19.94% in premarket trading following the announcement that it will present a late-breaking U.S.-based clinical trial update on its Lumee Oxygen tissue monitoring platform at the Paris Vascular Insights 2025 conference. The presentation, scheduled for December 13, 2025, will showcase the platform’s evaluation of transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients, a first-of-its-kind technology for continuous, real-time tissue oxygen monitoring. The late-breaking session slot at a prominent vascular surgery conference signals progress in clinical development, enhancing scientific credibility and visibility for Profusa’s innovation. While no efficacy or safety data were disclosed, the event underscores ongoing trial activity and aligns with the company’s strategy to advance its commercial-stage digital health platform. The premarket rally reflects investor optimism about the potential for regulatory or commercial milestones following the presentation.